Is Spero Therapeutics Stock a Good Investment?
Spero Therapeutics Investment Advice | SPRO |
- Examine Spero Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Spero Therapeutics' leadership team and their track record. Good management can help Spero Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Spero Therapeutics' business and its evolving consumer preferences.
- Compare Spero Therapeutics' performance and market position to its competitors. Analyze how Spero Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Spero Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Spero Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Spero Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Spero Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Spero Therapeutics Stock
Researching Spero Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 24.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run.
To determine if Spero Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spero Therapeutics' research are outlined below:
| Spero Therapeutics generated a negative expected return over the last 90 days | |
| Spero Therapeutics has some characteristics of a very speculative penny stock | |
| Spero Therapeutics has high historical volatility and very poor performance | |
| Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 |
Spero Therapeutics Quarterly Cash And Short Term Investments |
|
Spero Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spero Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spero Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Spero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Spero Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-14 | 2022-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2024-08-05 | 2024-06-30 | -0.38 | -0.33 | 0.05 | 13 | ||
2023-11-13 | 2023-09-30 | -0.03 | 0.04 | 0.07 | 233 | ||
2023-05-11 | 2023-03-31 | -0.33 | -0.25 | 0.08 | 24 | ||
2018-08-09 | 2018-06-30 | -0.77 | -0.69 | 0.08 | 10 | ||
2019-08-08 | 2019-06-30 | -0.65 | -0.74 | -0.09 | 13 | ||
2019-11-04 | 2019-09-30 | -0.85 | -0.95 | -0.1 | 11 | ||
2023-08-10 | 2023-06-30 | -0.34 | -0.23 | 0.11 | 32 |
Know Spero Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Spero Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spero Therapeutics backward and forwards among themselves. Spero Therapeutics' institutional investor refers to the entity that pools money to purchase Spero Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-12-31 | 184.8 K | Citadel Advisors Llc | 2024-12-31 | 172.9 K | State Street Corp | 2024-12-31 | 148.9 K | Dafna Capital Management Llc | 2024-12-31 | 125 K | Northern Trust Corp | 2024-12-31 | 86.4 K | Jpmorgan Chase & Co | 2024-12-31 | 61.6 K | Squarepoint Ops Llc | 2024-12-31 | 55.1 K | Jane Street Group Llc | 2024-12-31 | 52.9 K | Prudential Financial Inc | 2024-12-31 | 49.2 K | Anson Funds Management Lp | 2024-12-31 | 3.8 M | Pfizer Inc | 2024-12-31 | 2.4 M |
Spero Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 44.82 M.Market Cap |
|
Spero Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.11 | 0.12 | |
| Return On Equity | 0.19 | 0.20 |
Determining Spero Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Spero Therapeutics is a good buy. For example, gross profit margin measures Spero Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spero Therapeutics' profitability and make more informed investment decisions.
Evaluate Spero Therapeutics' management efficiency
As of the 24th of March 2025, Return On Tangible Assets is likely to grow to 0.12. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Spero Therapeutics' Return On Assets are very stable compared to the past year. As of the 24th of March 2025, Asset Turnover is likely to grow to 0.50, while Total Assets are likely to drop about 119.9 M. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.33 | 2.22 | |
| Tangible Book Value Per Share | 2.33 | 2.22 | |
| Enterprise Value Over EBITDA | 0.23 | 0.25 | |
| Price Book Value Ratio | 0.83 | 0.79 | |
| Enterprise Value Multiple | 0.23 | 0.25 | |
| Price Fair Value | 0.83 | 0.79 | |
| Enterprise Value | 6 M | 5.7 M |
The strategic initiatives led by Spero Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.686 |
Basic technical analysis of Spero Stock
As of the 24th of March, Spero Therapeutics has the Risk Adjusted Performance of (0.07), variance of 15.28, and Coefficient Of Variation of (1,186). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spero Therapeutics, as well as the relationship between them.Spero Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spero Therapeutics' Outstanding Corporate Bonds
Spero Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spero Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spero bonds can be classified according to their maturity, which is the date when Spero Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Spero Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Spero Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.59 | |||
| Coefficient Of Variation | (1,186) | |||
| Standard Deviation | 3.91 | |||
| Variance | 15.28 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 21.98 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.13 | |||
| Skewness | 1.66 | |||
| Kurtosis | 6.21 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.59 | |||
| Coefficient Of Variation | (1,186) | |||
| Standard Deviation | 3.91 | |||
| Variance | 15.28 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 21.98 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.13 | |||
| Skewness | 1.66 | |||
| Kurtosis | 6.21 |
Consider Spero Therapeutics' intraday indicators
Spero Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spero Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Spero Therapeutics time-series forecasting models is one of many Spero Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spero Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Spero Stock media impact
Far too much social signal, news, headlines, and media speculation about Spero Therapeutics that are available to investors today. That information is available publicly through Spero media outlets and privately through word of mouth or via Spero internal channels. However, regardless of the origin, that massive amount of Spero data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spero Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spero Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spero Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spero Therapeutics alpha.
Spero Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Spero Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Spero Therapeutics Corporate Management
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Susannah Walpole | Head Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Spero Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.